TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05495399

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spondylectomy
Description: Patient will be randomized to treated by spondylectomy or debulking surgery. Spondylectomy implied total resection of involved spine; while debulking surgery means partial resection of involved spine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spondylectomy
Description: Patient will be randomized to treated by spondylectomy or debulking surgery. Spondylectomy implied total resection of involved spine; while debulking surgery means partial resection of involved spine.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Patient received debulking surgery will be randomized to receive SBRT or conventional RT. SBRT means high dose per fraction compared to conventional RT.
Study: NCT05442775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv
Description: Oral tablet
Study: NCT05427955

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-level Erector Spinae Plane Block
Description: One-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 30 ml of 0.25% bupivacaine will be injected at the T5 level.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bi-level Erector Spinae Plane Block
Description: Bi-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 15 ml of 0.25% bupivacaine at T4 level and 15 ml of 0.25% bupivacaine at T6 level will be injected.
Study: NCT05461807

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data

Intervention type: DRUG
Intervention: Apixaban
Description: Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
Study: NCT04780438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Patients rendomized in this arm will receive dapagliflozin at a target dose of 10mg once daily.
Study: NCT05498220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (PV)
Description: 1.8 mg/kg, intravenous, at day 1, in every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 intravenous, at day 1 or day 2, in every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Description: 1,400 mg/23,400 units sub-cutaneous, starts at cycle 2, in every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000 mg/m2 intravenous at day 1 and 8, in every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2, intravenous, at day 1, in every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg intravenous at day 1, Per oral days at days 2-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF
Description: granulocyte-colony stimulating factor (GCSF )
Study: NCT05409612

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Supemtek®
Description: Quadrivalent recombinant high-dose influenza vaccine containing 45 µg of hemagglutinin (HA) for each of the 4 strains included (2 strains A and 2 strains B).~Solution for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigriptetra®
Description: Quadrivalent inactivated influenza vaccine containing 15 µg of hemagglutinin (HA) for each of the 4 strains included. Suspension for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.
Study: NCT04780438

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients rendomized in this arm will receive placebo.
Study: NCT06198660

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: positional release technique
Description: positional release techniques in addition to conventional therapy two sessions per week for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positional release technique
Description: positional release techniques in addition to conventional therapy two sessions per week for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy in addition to conventional therapy two sessions per week for 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy in addition to conventional therapy two sessions per week for 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy only
Description: conventional therapy two sessions for 6 weeks
Study: NCT05092503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JINZHEN Granules for Oral Solution
Description: JINZHEN granules will be dissolved in drinking water and administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JINZHEN Granules for Oral Solution
Description: JINZHEN granules will be dissolved in drinking water and administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JINZHEN Granules for Oral Solution
Description: JINZHEN granules will be dissolved in drinking water and administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules will be dissolved in drinking water and administered orally.
Study: NCT06237907

Intervention type: OTHER
Intervention: Patients underwent lymphedema surgery
Description: Patients who have developed lymphedema and undergone lymphedema surgery.

Intervention type: OTHER
Intervention: Patients underwent surgery without LVA
Description: For patients who have not experienced lymphedema but require surgery due to other disease such as cancer, trauma, chronic wounds, skin defects, etc.
Study: NCT04799639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sindilimab +paclitaxel+ cisplantin
Description: standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles
Study: NCT05298969

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporalis Myofascial flap
Description: Improvement of speech and feeding quality in patients with palatal defects by temporalis myofascial flap
Study: NCT04345211

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group1, walking group
Description: The walking group includes a weekly walking goal of 75 minutes.
Study: NCT05495399

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patient received debulking surgery will be randomized to receive SBRT or conventional RT. SBRT means high dose per fraction compared to conventional RT.
Study: NCT03238157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluocinolone Acetonide (FA) implant
Description: Fluocinolone Acetonide (FA) implant is designed to release FA at an initial rate of approximately 0.6 g/d, decreasing over the first month to a steady rate of 0.3 to 0.4 g/d with a duration of approximately 30 months.
Study: NCT04704128

Intervention type: OTHER
Intervention: Salivic sample
Description: Collection of total saliva not stimulated

Intervention type: OTHER
Intervention: Salivic sample
Description: Collection of total saliva not stimulated
Study: NCT06000904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame-based balance training
Description: For a four-week intervention consisting of three weekly sessions, each lasting 60 minutes. Each training session will include a 5-minute warm-up activity, 40-minute balance exercise, and 15-minute ground walking as a cool-down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb and trunk training
Description: For a four-week intervention consisting of three weekly sessions, each lasting 60 minutes. Each training session will include a 5-minute warm-up activity, 40-minute upper-limb and trunk exercise, and 15-minute ground walking as a cool-down.
Study: NCT06107686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL202 should be intravenously infused
Description: For each patient, YL202 should be intravenously infused over 60±10 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL202 should be intravenously infused
Description: For each patient, YL202 should be intravenously infused over 60±10 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL202 should be intravenously infused
Description: For each patient, YL202 should be intravenously infused over 60±10 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL202 should be intravenously infused
Description: For each patient, YL202 should be intravenously infused over 60±10 min.
Study: NCT06549127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Wearable Robot
Description: This study aims to enroll 20 participants who will receive assistance in flexion and extension of the knee and hip during overground walking adaptation training. Following the initial assessment, participants will undergo three 30-minute sessions of overground walking adaptation training with a powered hip assistive device over two weeks. After completing these sessions, Post-intervention Assessment 1 will be conducted. Then, participants will undergo three 30-minute sessions of overground walking adaptation training with a powered knee assistive device over two weeks, followed by Post-intervention Assessment 2. Each participant will have a total of nine visits, including three functional assessments and six adaptation training sessions. The first visit will involve scheduling subsequent visits. The familiarization process will occur two to three times per week, adjustable for participants' convenience, with each set of three visits completed within three weeks.
Study: NCT04895358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal doxorubicin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dextrose
Description: IV infusion
Study: NCT04345211

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2, Walking plus manual therapy
Description: Walking plus self-administered thorax manual therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 3; Walking plus exercises with Theraband
Description: Walking plus thorax exercises with Theraband
Study: NCT05611970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal pessary
Description: A reusable vaginal pessary for stress urinary incontinence
Study: NCT05599217

Intervention type: OTHER
Intervention: Dietary and nutritional questionnaire
Description: Nutrition assessment, nutrient intake, dietary inflammatory index, and frailty status will be examined using questionnaires.

Intervention type: OTHER
Intervention: Dietary and nutritional questionnaire
Description: Nutrition assessment, nutrient intake, dietary inflammatory index, and frailty status will be examined using questionnaires.

Intervention type: OTHER
Intervention: Neurological function, cognitive function, and life quality assessment
Description: Neurological function, cognitive function, and life quality will be examined using Glasgow Coma Scale, Modified Rankin Scale, Markwalder Grade Scale, Mini-mental state examination, and EuroQol five dimensions questionnaire.

Intervention type: OTHER
Intervention: Peripheral blood test
Description: Collect peripheral blood samples from patients.

Intervention type: OTHER
Intervention: Peripheral blood test
Description: Collect peripheral blood samples from patients.

Intervention type: OTHER
Intervention: Metabonomic test
Description: Collect urine and stool samples from patients.

Intervention type: OTHER
Intervention: Metabonomic test
Description: Collect urine and stool samples from patients.

Intervention type: OTHER
Intervention: Hematoma test
Description: Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
Study: NCT05373836

Intervention type: DIAGNOSTIC_TEST
Intervention: prognostic nutritional index calculated from laboratory parameters
Description: Calculated nutritional index using laboratory results of serum albumin, lymphocyte count, and cholesterol
Study: NCT04829214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-313
Description: Single intratympanic injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intratympanic injection
Study: NCT05737693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Week-long exposure therapy with ketamine infusion on day 2 and 4 of the psychotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Week-long exposure therapy with ketamine infusion on day 2 and 4 of the psychotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Week-long exposure therapy with midazolam infusion on day 2 and 4 of the psychotherapy
Study: NCT05315583

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of biological samples
Description: All participants will have at each of the visits: a venipuncture sample of 2 dry tubes of 7 mL to make up 3 aliquots and a nasopharyngeal swab (optional). The aliquots of serum / plasma and the nasopharyngeal swab will be stored at -80°C until sent to the Pasteur Institute.
Study: NCT06074523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Measurement and self-report
Description: Measurements of behavioral performance and self-report
Study: NCT04826614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optimized treatment
Description: early adjust dose or change drug

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: optimized treatment
Description: early adjust dose or change drug
Study: NCT05598307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium bolus followed by normal saline infusion
Description: a bolus dose of magnesium will be followed by normal saline infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium bolus followed by magnesium infusion
Description: a bolus dose of magnesium will be followed by a magnesium infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline bolus followed by normal saline infusion
Description: a bolus of normal saline will be followed by normal saline infusion
Study: NCT04678960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trust-based Relational Intervention Training
Description: The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI Group Training is comprised of three components: TBRI Youth Group Training (youth only), Caregiver Training (caregivers only), and Nurture Groups (youth-caregiver joint roleplay activities), which is conducted prior to youth's release.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trust-based Relational Intervention Training
Description: The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI Group Training is comprised of three components: TBRI Youth Group Training (youth only), Caregiver Training (caregivers only), and Nurture Groups (youth-caregiver joint roleplay activities), which is conducted prior to youth's release.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trust-based Relational Intervention Training
Description: The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI Group Training is comprised of three components: TBRI Youth Group Training (youth only), Caregiver Training (caregivers only), and Nurture Groups (youth-caregiver joint roleplay activities), which is conducted prior to youth's release.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trust-based Relational Intervention In-Home Structured Coaching
Description: The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI In-Home Structured Training includes four structured in-home coaching sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trust-based Relational Intervention In-Home Responsive Coaching
Description: The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI In-Home Responsive Training includes at least 2 structured in-home coaching sessions plus additional sessions indefinitely as needed.
Study: NCT06628271

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Guidelines
Description: Participant with typical spells will be investigated according to our guidelines. These include that participants with heredity for or signs and symptoms of cardiac disease will be subjected to an ECG and participants with two or more spells should be subjected to blood tests for anemia and iron deficiency
Study: NCT06433232

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROOT CANAL TREATMENT
Description: ROOT CANAL TREATMENT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ROOT CANAL TREATMENT
Description: ROOT CANAL TREATMENT
Study: NCT05616780

Intervention type: OTHER
Group type: OTHER
Intervention: Physiological test
Description: Lung volume measurements will be obtained using nitrogen washout and body plethysmography
Study: NCT06305962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-RAD204
Description: 177Lu-RAD204 administered at Imaging (im) and Treatment (tr) doses
Study: NCT06009354

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The control group will receive post-operative usual practices. The study group will receive multi-component education in addition to the usual practices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The control group will receive post-operative usual practices. The study group will receive multi-component education in addition to the usual practices.
Study: NCT05682573

Intervention type: DIAGNOSTIC_TEST
Intervention: hospitalized patient
Description: Collect the patient's whole blood for testing
Study: NCT06273865

Intervention type: DIAGNOSTIC_TEST
Intervention: Several assays
Description: Standard blood draw by venipuncture is performed in all study participants to collect blood samples in four 2.7 mL citrated blood tubes. Tube one is a dummy tube and is discarded. Tube two is used for the FVIII activity and thrombin generation assay on the EnzySystem. Tube three is used to perform conventional FVIII activity and thrombin generation assays. Tube four is used for duplicate measurements of the conventional assays and measurement of prothrombin F1+2 antigen levels, ADAMTS13 activity, FVIII antigen, VWF (von Willebrand Factor) antigen and von Willebrand ristocetin cofactor activity levels.

Intervention type: DIAGNOSTIC_TEST
Intervention: Several assays
Description: Standard blood draw by venipuncture is performed in all study participants to collect blood samples in four 2.7 mL citrated blood tubes. Tube one is a dummy tube and is discarded. Tube two is used for the FVIII activity and thrombin generation assay on the EnzySystem. Tube three is used to perform conventional FVIII activity and thrombin generation assays. Tube four is used for duplicate measurements of the conventional assays and measurement of prothrombin F1+2 antigen levels, ADAMTS13 activity, FVIII antigen, VWF (von Willebrand Factor) antigen and von Willebrand ristocetin cofactor activity levels.
Study: NCT03070132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study: NCT06067646

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Semistructured interview
Description: Semistructured interview and validated quality of life assesment using EQ5-DL